Raymond L. Woosley, MD, PhD - 2012 AZBio Pioneer
Raymond L. Woosley earned a Ph.D. in Pharmacology from the University of Louisville and an M.D. from the University of Miami. He began his career as the first scientist in the US operations for Glaxo, now known as GlaxoSmithKline. Dr. Woosley specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University where he rose to the rank of Professor of Medicine. At Georgetown University he served as Chairman of the Department of Pharmacology and in 2000 was appointed Associate Dean for Clinical Research. In 2001 he became Vice President for Health Sciences at the University of Arizona and Dean of the College of Medicine. In January of 2005 he assumed the position of President of The Critical Path Institute (C-Path), a non-profit corporation formed by the Food and Drug Administration, SRI, International and the University of Arizona to accelerate the development of safe innovative medicines. Since 1999, he has directed one of seven federally-funded (Agency for Healthcare Research and Quality) Centers for Education and Research on Therapeutics (CERT).Under Dr. Woosley’s leadership, C-Path (the Critical Path Institute) orchestrated the acceleration of medical product development through a unique collaborative process among industry, academia, and the FDA. Our collaborations among 6 global consortia, 1000+scientists, and 41 companies has already produced these notable successes: First preclinical safety biomarkers (7) qualified by the FDA, EMA, and PMDA (the Japanese counterpart) First CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard First and largest open database of CDISC aggregated clinical trial data for Alzheimer’s disease (6,100 patients and 22 clinical trials) Read more First drug-disease trial model & clinical trial simulation tool submitted and under review by the FDA First imaging biomarker for trial enrichment qualified by the EMA Dr. Woosley’s research has investigated the basic and clinical pharmacology of drugs for the treatment of arrhythmias and the cardiac toxicity of drugs, and has been published in over 260 publications. His research discovered the mechanism of the toxicity of the antihistamine Seldane®. He is the recipient of the Rawls-Palmer Award from the American Society of Clinical Pharmacology and Therapeutics for his contributions to medicine and the FDA Commissioner’s Special Citation for his work to advise the agency on the toxicity of dietary supplements containing ephedra. Dr. Woosley is a Past-President of the Association for Medical School Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. He has served on numerous boards including the US Pharmacopeia. He is a member of the Biodesign Institute at Arizona State University. As a member of the University of Arizona’s Sarver Heart Center and Bio5 Institute, he conducts research on the prevention of adverse drug interactions.
David S Alberts AZBio Pioneer
David S. Alberts, MD. Throughout his career, Dr. Alberts has focused on translational cancer prevention and treatment research. The emphasis of his laboratory-based and clinical research has been on the chemoprevention and treatment of such pervasive and potentially deadly diseases as cancers of the breast, colon, ovary, and skin. He has been the UA Cancer Center’s director since 2005. Under Dr. Alberts’ leadership the extensive research portfolio of The University of Arizona Cancer Center includes more than $60 million in annual research funding, including four large NCI interdisciplinary programs, and two Special Programs of Research Excellence, one in gastrointestinal cancers and one in lymphoma. Clinically, Dr. Alberts pioneered new treatments for advanced ovarian cancers, including in vitro tumor cell chemosensitivity testing for personalized medicine strategies, intraperitoneal chemotherapy , and maintenance chemotherapy. Presently, Dr. Alberts helps to coordinate Phase I and II and pharmacokinetic drug studies at The University of Arizona Cancer Center for molecularly-targeted chemopreventive agents. His laboratory research is concentrated on the evaluation of new surrogate endpoint biomarkers for cancer prevention trials with a special focus on precursor lesions for bladder, breast, colon, cervical, endometrial, ovarian, prostate, and skin cancers, using quantitative histopathology (i.e. karyometric) approaches. His NCI funded drug and diagnostics research has resulted in more than two dozen patents and the co-founding of five Arizona pharmaceutical and biotechnology companies.
Arizona Commerce Authority05/17/2013
AZ Innovation Challenge Video
The Arizona Innovation Challenge (AIC), powered by the Arizona Commerce Authority , awards the most money in the country for a technology commercialization challenge – $3 million ($1.5 million twice yearly) to the world’s most promising technology ventures. Awards range from $100,000 to $250,000 per company. The results? A big-time investment in the most talented entrepreneurs. Bringing to market products that are literally changing the way the world works. Driving wealth and job creation for the state of Arizona. Are you up for the Challenge?
Nasseo moves into the Fast Lane
Nasseo, Inc. is a start-up medical device company developing an implant surface modification technology to provide patients and clinicians with the next generation of dental and orthopedic implants. Over the past 18 months the company has achieved very impressive milestones and is in the Fast Lane to delivering a new platform technology that benefits patients in several compelling markets. In 2013 NASSEO was accepted into the BioInspire Medical Device accelerator in Peoria, AZ. In addition to mentoring and support, NASSEO received a $300,000 investment of seed funding from the highly competitive program. NASSEO was also named the 2013 Innovation Challenge Winner by the Arizona Commerce Authority (ACA) in its spring Arizona Innovation Challenge securing $250,000 for the commercialization of its first product, the TiArray™ Dental Implant which received FDA approval in 2013.
Senestech: Humane Pest Control
Senestech is a platform biotechnology company specializing in reproductive physiology. Our mission: Senestech aims to provide for the more humane treatment of animals, to improve the quality of human life, and to enhance environmental stewardship through global application of our animal fertility control technology. We are currently applying our revolutionary technology to the control of rats and mice in both agricultural and urban settings.
AZBio and SynCardia on ABC15
By: Christina Estes ABC15 Tucson-based SynCardia Systems was among the companies showcased at the annual AZ Bio Expo.It’s a chance for bioscience and technology companies to learn more about funding opportunities and hear success stories.According to the Arizona BioIndustry Association, our state is getting more federal funding for research and seeing higher job growth in the bioscience industry compared to the national average.“Tucson and Arizona are the international headquarters for the world’s only total artificial heart,” said Don Isaacs, SynCardia vice president of communications. “They replace the exact same parts of the heart as if you had a heart transplant.”The SynCardia heart is made in Arizona using bio-compatible material also made here. Isaacs says they have 82 employees in Arizona and about 80 people currently using the heart. The device is considered a bridge for people awaiting a transplant or a life saver for those who will not get transplants due to age or medical conditions.“There’s only 2,200 hearts available per year in the United States and the level of donors has been the same for the last twenty years,” Isaacs said.SynCardia is also undergoing FDA clinical trials for the world’s first wearable power supply for their temporary artificial heart. ©2007 The E.W. Scripps Co. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. (Republished with permission from ABC15) Read more: http://www.abc15.com/dpp/news/region_southeast_valley/tempe/Arizona-company-SynCardia-Systems-makes-worlds-first-total-temporary-artificial-heart#ixzz2X99ewU3x